Patents
Literature
3 results about "Human Immunoglobulin G" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Immunoglobulin G (IgG) is a monomeric immunoglobulin, built of two heavy chains and two light chains. Each molecule has two antigen binding sites. It is the most abundant immunoglobulin and is approximately equally distributed in blood and in tissue liquids, and is the class of immunoglobulin characterized by heavy chains.
CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
ActiveUS12589132B2Antibody mimetics/scaffoldsPeptide/protein ingredientsHuman immunoglobulinsExtracellular
The present disclosure provides methods of treating PD-L1 negative tumors, the methods comprising administering fusion proteins comprising the extracellular domain of human cluster of differentiation 80 (CD80) and the fragment crystallizable (Fc) domain of human immunoglobulin G 1 (IgG1).
Owner:FIVE PRIME THERAPEUTICS INC
Stable liquid formulation of fusion protein having igg fc domain
The present invention relates to a stable liquid formulation of a fusion protein having an Fc domain of human immunoglobulin G (IgG) (in particular, a protein in which a soluble extracellular domain of a vascular endothelial growth factor (VEGF) receptor and an Fc domain of human immunoglobulin G (IgG) are fused (e.g. Aflibercept)). The present invention also relates to a composition for stabilizing a protein in which a soluble extracellular domain of a VEGF receptor and an Fc domain of IgG are fused, and a method for stabilizing a protein in which a soluble extracellular domain of a VEGF receptor and an Fc domain of IgG are fused. The present invention can promote stabilization of physiological activity through a stable liquid formulation suitable for intravitreal injection of anti-VEGF-Fc fusion proteins including Aflibercept, and improve the therapeutic effect on various ophthalmic diseases caused by abnormal angiogenesis (e.g., retinal vein occlusion, diabetic macular edema, choroidal neovascularization, and wet age-related macular degeneration, etc.).
Owner:ALTEOGEN INC
Rabbit antibodies against human immunoglobulin G
PendingJP2026049726AImmunoglobulins against animals/humansBiological testingHuman immunoglobulinsAntigen binding
This invention provides a monoclonal antibody that is universally specific to human IgG but does not bind to monkey IgG. [Solution] An anti-human IgG antibody obtained from rabbits, its antigen-binding portion, and a method for using the antibody and portion are provided.
Owner:GENZYME CORP